NIKA PHARMACEUTICALS Changes Certifying Accountant
Ticker: NIKA · Form: 8-K · Filed: Feb 16, 2024 · CIK: 1145604
| Field | Detail |
|---|---|
| Company | Nika Pharmaceuticals, Inc (NIKA) |
| Form Type | 8-K |
| Filed Date | Feb 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, auditor-change
TL;DR
**NIKA PHARMACEUTICALS just swapped out their accountant, keep an eye on their next financials.**
AI Summary
NIKA PHARMACEUTICALS, INC. (CIK: 0001145604) filed an 8-K on February 16, 2024, reporting a change in its certifying accountant, with the earliest event date being February 14, 2024. The company, based in Henderson, NV, with a business phone of 702-326-3615, previously operated under the name CENTENNIAL GROWTH EQUITIES INC until July 24, 2001. This filing indicates a standard procedural change in its financial oversight.
Why It Matters
A change in a company's certifying accountant can sometimes signal underlying issues or a shift in financial strategy, impacting investor confidence.
Risk Assessment
Risk Level: low — This filing only reports a change in the certifying accountant, which is a common administrative event and does not inherently indicate significant risk without further context.
Key Players & Entities
- NIKA PHARMACEUTICALS, INC. (company) — Registrant
- CENTENNIAL GROWTH EQUITIES INC (company) — Former Company Name
- February 14, 2024 (date) — Date of earliest event reported
- February 15, 2024 (date) — Date of Report
- February 16, 2024 (date) — Filed as of date
- Henderson, NV (location) — Business Address City/State
- 702-326-3615 (dollar_amount) — Registrant's telephone number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was February 14, 2024.
What is the primary purpose of this 8-K filing by NIKA PHARMACEUTICALS, INC.?
The primary purpose of this 8-K filing is to report 'Changes in Registrant's Certifying Accountant'.
When was NIKA PHARMACEUTICALS, INC. formerly known as CENTENNIAL GROWTH EQUITIES INC?
NIKA PHARMACEUTICALS, INC. changed its name from CENTENNIAL GROWTH EQUITIES INC on July 24, 2001.
What is the business address of NIKA PHARMACEUTICALS, INC.?
The business address of NIKA PHARMACEUTICALS, INC. is 2269 Merrimack Valley Avenue, Henderson, NV 89044.
What is the Commission File Number for NIKA PHARMACEUTICALS, INC.?
The Commission File Number for NIKA PHARMACEUTICALS, INC. is 000-56234.
Filing Stats: 396 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-02-15 20:03:01
Filing Documents
- form8k.htm (8-K) — 12KB
- exhibit23-1.htm (EX-23) — 2KB
- exhibit23x1x1.jpg (GRAPHIC) — 4KB
- exhibit23x1x2.jpg (GRAPHIC) — 1KB
- 0001826466-24-000005.txt ( ) — 181KB
- nika-20240214.xsd (EX-101.SCH) — 3KB
- nika-20240214_lab.xml (EX-101.LAB) — 33KB
- nika-20240214_pre.xml (EX-101.PRE) — 22KB
- form8k_htm.xml (XML) — 3KB
01 Changes in Registrants Certifying
Item 4.01 Changes in Registrants Certifying Accountant. The Nika Pharmaceuticals, Inc. board of directors deemed it in the best interests of the company to dismiss independent accountant B F Borgers CPA PC on February 14, 2024 and engage Fruci & Associates II, PLLC. The members of the board of directors have discussed the issue with the former independent accountant, and Nika Pharmaceuticals, Inc. has authorized the former independent accountant to respond fully to the inquiries of the successor accountant concerning historical data. On February 14, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Fruci & Associates II, PLLC to serve as the independent accountant to audit the companys financial statements. The Nika Pharmaceuticals, Inc. board of directors has the highest regard for B F Borgers CPA PC and wishes it success in all its future endeavors.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 23.1 Nika Pharmaceuticals Inc. Dismissal Consent by B F Borgers CPA PC
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: February 15, 2024 By: /s/ Dimitar Slavchev Savov Dimitar Slavchev Savov Chief Executive Officer, Director